iBio, Inc. (IBIO) financial statements (2021 and earlier)

Company profile

Business Address 600 MADISON AVENUE, SUITE 1601
NEW YORK, NY 10022-1737
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments91554168239
Cash and cash equivalents91554168239
Receivables0000010
Prepaid expense      0
Other current assets      0
Other undisclosed current assets1970000 
Total current assets:1116251692410
Noncurrent Assets
Finance lease, right-of-use asset2728
Property, plant and equipment54242526260
Intangible assets, net (including goodwill)1112222
Intangible assets, net (excluding goodwill)1112222
Other undisclosed noncurrent assets200000 
Total noncurrent assets:3532262727282
TOTAL ASSETS:145943143365212
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4322221
Accounts payable2211111
Accrued liabilities2111110
Deferred revenue12
Debt110000 
Due to related parties      0
Contract with customer, liability1
Other undisclosed current liabilities    00 
Total current liabilities:6532221
Noncurrent Liabilities
Long-term debt and lease obligation323225252525 
Long-term debt, excluding current maturities00     
Finance lease, liability3232
Capital lease obligations25252525 
Total noncurrent liabilities:323225252525 
Other undisclosed liabilities      (0)
Total liabilities:3838282727281
Stockholders' equity
Stockholders' equity attributable to parent1075721691011
Common stock0000000
Additional paid in capital273207108104816759
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(166)(150)(106)(88)(72)(58)(48)
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)(0)014 
Total stockholders' equity:1075721692411
TOTAL LIABILITIES AND EQUITY:145943143365212

Income statement (P&L) ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Revenue, net 012
Gross profit:2220012
Operating expenses(24)(16)(18)(15)(15)(11)(9)
Operating loss:(21)(14)(16)(14)(14)(10)(7)
Nonoperating income (expense)(2)(2)(2)(2)(2)(1)0
Investment income, nonoperating0000000
Interest and debt expense(2)(2)(2)(2)(2)(1) 
Loss from continuing operations before income taxes:(26)(19)(19)(18)(18)(11)(7)
Income tax benefit      3
Loss before gain (loss) on sale of properties:(26)(19)(19)(18)(18)(11)(4)
Other undisclosed net income222221 
Net loss:(24)(16)(18)(16)(16)(11)(4)
Net income attributable to noncontrolling interest000021 
Other undisclosed net loss attributable to parent      (3)
Net loss attributable to parent:(24)(16)(18)(16)(15)(10)(7)
Other undisclosed net loss available to common stockholders, basic(0)(22)(0)(0)(0)  
Net loss available to common stockholders, diluted:(24)(38)(18)(16)(15)(10)(7)

Comprehensive Income ($ in millions)

12/31/2020
TTM
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(24)(16)(18)(16)(16)(11)(4)
Other undisclosed comprehensive loss(0)(0)(0)(0) (0)(3)
Comprehensive loss:(24)(16)(18)(16)(16)(11)(7)
Comprehensive income, net of tax, attributable to noncontrolling interest000021 
Comprehensive loss, net of tax, attributable to parent:(24)(16)(18)(16)(15)(10)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: